Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC vs Aspirin in VT Ablation (STROKE-VT)
NCT02666742Phase 4Completed
- Sponsor
- Kansas City Heart Rhythm Institute
- Start
- Feb 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of apixaban in stroke, Transient Ischemic Attack (TIA), sponsored by Kansas City Heart Rhythm Institute. Started Feb 2017; status: completed.
02
Drugs
apixaban
03
Conditions
strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02666742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666742.